During Phase 3 experiments Lorcaserin demonstrated to be a tolerable medication. Trial patients told Lorcaserin was as mild as placebo, with seven percent of the patients in both the medication and placebo arms falling out because of adverse events.
Lorcaserin’s were spotted to have the lowest cessation rates because of side effects of any weight loss medication in a phase 3 experiments, comparing to discontinuance rates because of side effects for (%):
- - Contrave-Placebo (26-13)
- - Qnexa Placebo (18-9)
- - Orlistat-Placebo (7-4)
- - Sibutramine-Placebo (9-9)
- - Rimonabant-Placebo (15-7).
Lorcaserin’s adverse events tested in clinical experiments did not considerably differ in rates than placebo’s ones. The most frequent one was headache, undergone by almost a quarter of medication arm patients in comparison to 10 percent of placebo participants.
Other found adverse events and their levels for lorcaserin placebo participants were as follows (%):
- nasopharyngitis (13,5-12,1),
- antritis (7,3-8,3)
- vomit (7,4-5,5).
Lorcaserin side effects like nervousness, depression and suicidal propensity were uncommon and of the same rate in each experimental division.
Concerning the cardiovascular risks of Lorcaserin, Arena managed to exclude a 20 percent growth in the rate of cardiovascular problems and, in a protocol with the FDA specified regular cardiograms of the phase 3 patients. The cardiograms of patients (during various time sections) of the Phase-3 BLOOM experiments did not demonstrate any considerable growth in cardiovascular risks.
Arena claims that results from Phase II clinical experiments of the drug showed that participants who had taken in the drug had undergone considerably much more weight reduction than participants who had taken placebo.
Results
1. At the end of 3 month term, the divisions which were given lorcaserin to dropped at an average 4 pounds, 5,8 pounds, and 7,9 pounds. The placebo participants dropped at an average 0,7 pounds, in spite that all participants were prescribed no low-fat diets or work outs at all.
2. On discontinuance of lorcaserin trials, dropped weight rises again. In Phase II clinical experiments, the participants were monitored for 14 days after trial cessation, and all participants regained pounds quicker than they had dropped it.
3. If you want to buy lorcaserin, you need to wait till October, 22 when the final decision on whether to approve the drug or not, will be made by FDA. Till then the medication is restricted for markerting (it is planned to sell lorcaserin under brandname Lorqess).
